Loading...
XSHE
300723
Market cap3.79bUSD
Jul 15, Last price  
60.86CNY
1D
13.19%
1Q
58.28%
IPO
508.60%
Name

ApicHope Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
147.22
P/S
10.86
EPS
0.41
Div Yield, %
0.35%
Shrs. gr., 5y
0.17%
Rev. gr., 5y
11.86%
Revenues
2.50b
+9.79%
507,566,827792,554,7911,028,297,4631,250,837,3141,380,217,2711,429,554,2971,637,405,5691,675,417,0582,199,214,4232,280,198,6012,503,447,003
Net income
185m
-36.49%
32,993,60740,310,09760,420,200137,349,512156,695,290208,224,368143,685,749225,610,583306,915,390290,682,890184,613,302
CFO
458m
-3.68%
135,680,7008,741,92334,549,505146,008,439141,348,771238,599,800280,649,860275,221,007438,100,615475,534,829458,051,312
Dividend
Jun 03, 20240.21 CNY/sh

Profile

ApicHope Pharmaceutical Co., Ltd, together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. It offers anti-infection, pediatric, cardiovascular, genitourinary, respiratory, liver and digestion, and dermatological products, as well as anti-inflammatory and analgesic products. The company was formerly known as Yipinhong Pharmaceutical Co.,Ltd and changed its name to ApicHope Pharmaceutical Co., Ltd in December 2021. ApicHope Pharmaceutical Co., Ltd was founded in 2002 and is based in Guangzhou, China.
URL
http://www.gdyph.com/
IPO date
Nov 16, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,503,447
9.79%
2,280,199
3.68%
Cost of revenue
2,031,341
1,802,920
Unusual Expense (Income)
NOPBT
472,106
477,278
NOPBT Margin
18.86%
20.93%
Operating Taxes
92,390
64,317
Tax Rate
19.57%
13.48%
NOPAT
379,716
412,962
Net income
184,613
-36.49%
290,683
-5.29%
Dividends
(56,632)
(56,596)
Dividend yield
0.43%
0.58%
Proceeds from repurchase of equity
(306)
BB yield
0.00%
Debt
Debt current
530,208
577,717
Long-term debt
212,068
648,461
Deferred revenue
83,341
75,755
Other long-term liabilities
2
1
Net debt
(313,796)
196,145
Cash flow
Cash from operating activities
458,051
475,535
CAPEX
(334,458)
Cash from investing activities
(578,990)
Cash from financing activities
99,760
FCF
170,102
(148,808)
Balance
Cash
462,962
717,785
Long term investments
593,110
312,249
Excess cash
930,899
916,023
Stockholders' equity
1,891,777
1,692,140
Invested Capital
2,575,464
2,427,746
ROIC
15.18%
19.01%
ROCE
13.28%
14.03%
EV
Common stock shares outstanding
439,555
420,829
Price
29.83
29.41%
23.05
-3.68%
Market cap
13,111,940
35.17%
9,700,107
-5.79%
EV
12,873,978
10,010,842
EBITDA
654,309
574,728
EV/EBITDA
19.68
17.42
Interest
37,654
24,453
Interest/NOPBT
7.98%
5.12%